Flagship Pioneering launched Expedition Medicines with a $50 million commitment to develop a covalent‑binding small‑molecule discovery platform targeting cancer and immune diseases. The newly revealed venture emerges from Flagship’s incubation model and already signals early industry partnerships, including collaborations to push specific discovery programs toward IND. Expedition aims to apply advanced chemistry and AI-driven design to unlock targets traditionally considered undruggable by reversible binders.